

---

18. (Twice Amended) An injectable pharmaceutical composition comprising:

a dispersion in an aqueous carrier solution comprising one or more pharmaceutically acceptable tonicity modifier agents and liquid droplets having a size range of micrometer to submicrometer, the droplets comprising

a substantially water-insoluble, pharmaceutically acceptable lipophilic liquid vehicle with at least one membrane-forming lipid that does not tend to form micelle structures and a camptothecin dissolved in the lipophilic liquid vehicle, and

an outer layer surrounding the droplet comprising at least one membrane-forming amphipathic lipid,

wherein upon thermal sterilization the dispersion does not aggregate, flocculate, agglomerate, or coalesce, and the droplets do not grow in size above a volume weighted mean diameter of 10  $\mu\text{m}$ .

19. (Twice Amended) An injectable pharmaceutical composition comprising:

an aqueous carrier solution comprising one or more pharmaceutically acceptable tonicity modifier agents;

a dispersion of liquid droplets of a first size distribution, the liquid droplets comprising

a substantially water-insoluble, pharmaceutically acceptable lipophilic liquid vehicle that does not tend to form micelle structures,

solid particles of a camptothecin of a second size distribution, and

an outer layer surrounding the droplet comprising at least one membrane-forming amphipathic lipid;

wherein the first size distribution is in the range of submicrometer to micrometers, and the second size distribution is smaller than the first size distribution; and

wherein upon thermal sterilization, the dispersion does not aggregate, flocculate, agglomerate, or coalesce, and the droplets do not grow in size above a volume weighted mean diameter of 10  $\mu\text{m}$ .

---

22. (Amended) An injectable pharmaceutical composition according to claim 20 wherein the phospholipid is selected from the group consisting of natural and synthetic lipids, hen egg-derived phospholipid, egg phospholipid, purified egg phospholipid, soy phospholipid, dimyristoyl lecithin, didodecanoyl lecithin, dioleoyl lecithin, dilinoleoyl lecithin, alpha-palmito-beta-oleoyl lecithin, alpha-palmitoyl-beta-linoleoyl lecithin, alpha-oleoyl-beta-palmitoyl lecithin, diarachidonoyl lecithin, alpha-palmito-beta-myristoyl lecithin, dimyristoyl phosphatidic acid, dipalmitoyl phosphatidic acid, distearoyl phosphatidic acid, phosphatidyl serine, phosphatidyl inositol, dimyristoyl phosphatidyl glycerol, dipalmitoyl phosphatidyl glycerol, dioctadecanoyl phosphatidyl ethanolamine, dioleoyl phosphatidyl ethanolamine, dihexadecyl phosphatidyl ethanolamine, dilauryl phosphatidyl ethanolamine, dimyristoyl phosphatidyl ethanolamine and dipalmitoyl phosphatidyl ethanolamine.

23. (Amended) An injectable pharmaceutical composition according to claim 20 wherein the phospholipid comprises egg phospholipid.

Please add the following new claims 31-36.

31. An injectable pharmaceutical composition according to claim 18 wherein the camptothecin is selected from the group consisting of 9-nitro-20(S)-camptothecin, 9-amino-20(S)-camptothecin, 9-methyl-camptothecin, 9-chloro-camptothecin, 9-flouro-camptothecin, 7-ethyl camptothecin, 10-methyl-camptothecin, 10-chloro--camptothecin, 10-bromo-camptothecin, 10-fluoro-camptothecin, 9-methoxy-camptothecin, 11-fluoro-camptothecin, 7-ethyl-10-hydroxy camptothecin, 10,11-methylenedioxy camptothecin, and 10,11-ethylenedioxy camptothecin, and 7-(4-methylpiperazinomethylene)-10,11-methylenedioxy camptothecin.

32. An injectable pharmaceutical composition according to claim 18 wherein the camptothecin is selected from the group consisting of 9-nitro-20(S)-camptothecin, 9-amino-20(S)-camptothecin, 7-ethyl-10-(4-(1-piperdino)-1-piperdino)-carbonyloxy-camptothecin, 7-ethyl-10-hydroxy-20(S)-camptothecin,

5 10,11-methylenedioxy-20(S)-camptothecin, 9-chloro-20(S)-camptothecin, 9-bromo-20(S)-  
6 camptothecin, 9-hydroxy-20(S)-camptothecin, and 11-hydroxy-20(S)-camptothecin.

1 33. An injectable pharmaceutical composition according to claim 18 wherein the  
2 camptothecin is 9-nitro-20(S)-camptothecin.

1 34. An injectable pharmaceutical composition according to claim 19 wherein the  
2 camptothecin is selected from the group consisting of 9-nitro-20(S)-camptothecin, 9-amino-  
3 20(S)-camptothecin, 9-methyl-camptothecin, 9-chloro-camptothecin, 9-flouro-camptothecin,  
4 7-ethyl camptothecin, 10-methyl-camptothecin, 10-chloro--camptothecin, 10-bromo-  
5 camptothecin, 10-fluoro-camptothecin, 9-methoxy-camptothecin, 11-fluoro-camptothecin, 7-  
6 ethyl-10-hydroxy camptothecin, 10,11-methylenedioxy camptothecin, and 10,11-  
7 ethylenedioxy camptothecin, and 7-(4-methylpiperazinomethylene)-10,11-methylenedioxy  
8 camptothecin.

1 35. An injectable pharmaceutical composition according to claim 19 wherein the  
2 camptothecin is selected from the group consisting of 9-nitro-20(S)-camptothecin, 9-amino-  
3 20(S)-camptothecin, 7-ethyl-10-(4-(1-piperdino)-1-piperdino)-carbonyloxy-camptothecin, 7-  
4 ethyl-10-hydroxy-20(S)-camptothecin, 10,11-methylenedioxy-20(S)-camptothecin, 9-chloro-  
5 20(S)-camptothecin, 9-bromo-20(S)-camptothecin, 9-hydroxy-20(S)-camptothecin, and 11-  
6 hydroxy-20(S)-camptothecin.

1 36. An injectable pharmaceutical composition according to claim 19 wherein the  
2 camptothecin is 9-nitro-20(S)-camptothecin.

---